Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome
- Registration Number
- NCT00551343
- Lead Sponsor
- Garvan Institute of Medical Research
- Brief Summary
The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).
- Detailed Description
Prader-Willi Syndrome (PWS) is the most frequent known genetic disorder of obesity. Hyperphagia is the main barrier to independent living in adults with PWS, and hitherto behavioural restraints and environmental modification are the only effective management measure. The emerging costs for professional care are immense. Thus, there is an urgent need for treatment which reduce appetite and food intake in this patient group. Agonists of the gut derived hormone GLP-1 which reduces food intake and causes weight loss due to slowed gastric emptying and through direct central effects. The aim of this pilot drug trial is to analyse the effect of a GLP-1 agonist on appetite regulating hormones, insulin secretion and energy expenditure before and after a meal.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- see below
- Diabetes mellitus, acute infections
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Controls Exenatide - PWS Exenatide -
- Primary Outcome Measures
Name Time Method satiety hormones 1 day
- Secondary Outcome Measures
Name Time Method appetite (visual analogue scale) insulin secretion 1 day
Trial Locations
- Locations (1)
Garvan Institute of Medical Research
🇦🇺Sydney, New South Wales, Australia